HaCaT

spontaneously transformed human keratinocyte cell line

Cell Type:
Skin/Hair Epith.
Tissue Origin:
dermal
Species:
human
Research Area:
Cancer Research/Cell Biology
Dermatology/Tissue Engineering
Cell Characteristics:
Adherent

Recommended Media

RPMI-1640 medium was developed by Moore et al., at Roswell Park Memorial Institute, hence the acronym RPMI. The formulation is based on the RPMI-1630 series of media utilizing a bicarbonate buffering system and alterations in the amounts of amino acids and vitamins. RPMI-1640 medium has been used for the culture of human normal and neoplastic leukocytes. RPMI-1640 when properly supplemented, has demonstrated wide applicability for supporting growth of many types of cell cultures, including fresh human lymphocytes in the 72-hour phytohemagglutinin (PHA) stimulation assay.

There are a variety of formulations:
12-702         - with L-glutamine
BE12-702/U1 - with UltraGlutamineI
BE15-702D    - [powder] with L-glutamine
12-167          - without L-glutamine
12-115          - with L-glutamine and 25 mM HEPES buffer
BE12-115/U1 - with UltraGlutamineI and 25 mM HEPES buffer
04-525          - with L-glutamine and 165 nM MOPS (used for some mycological assays)
09-774          - with L-glutamine, 25 mM HEPES buffer 100 units/ml penicillin, 50 ug/ml streptomycin
12-918          - without L-glutamine or phenol red
BE12-752       - with L-glutamine, without D-glucose

Storage = 2ºC to 8ºC 
  (versions without L-glutamine and those with UltraGlutamine can be stored at 15ºC to 30ºC)

Dulbecco's Modified Eagle Medium (DMEM) was developed in 1969 and is a modification of Basal Medium Eagle (BME) that differs from BME and MEM by the following characteristics:

  • Vitamins 4X greater than MEM. Vitamins and amino acids greater than BME
  • Types and quantities of amino acids greater than MEM and BME
  • Iron (ferric nitrate)

It is used in a wide range of mammalian cell culture applications.  The high glucose version is well suited to high density suspension culture. The low glucose formula is used for adherent dependent cells.

Storage = 2ºC to 8ºC

Liquid:
12-614 = 4.5 g/L glucose, without L-glutamine
12-604 = 4.5 g/L glucose, with L-glutamine
BE12-604/U1 = 4.5 g/L glucose, with Ultraglutamine I
12-914 = 4.5 g/L glucose, without L-glutamine (hybridoma screened)
12-917 = 4.5 g/L glucose, without L-glutamine or phenol red
12-709 = 4.5 g/L glucose and 25 mM HEPES, without L-glutamine
12-733= 4.5 g/L glucose, without L-glutamine or sodium pyruvate
12-741 = 4.5 g/L glucose, with L-glutamine, without sodium pyruvate

12-707 = 1.0 g/L glucose, without L-glutamine
12-708 = 1.0 g/L glucose and 25 mM HEPES, without L-glutamine

Powder:
15-614 = 4.5 g/L glucose, without L-glutamine or sodium pyruvate
15-604 = 4.5 g/L glucose, with L-glutamine or sodium pyruvate

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
V

U-020

1e6 31-55%


Plasmid (general) 2 µg 100 µl I/II/2b

Citations (12)

Categories:
Primary Cells and Media, Classical Media and Reagents 
Authors:
Cecchetti S, Bortolomai I, Ferri R, Mercurio L, Canevari S, Podo F, Miotti S, Iorio E. 
In:
PLoS ONE (2015) 10(9): e0136120 
Categories:
Transfection 
Authors:
He YY, Council SE, Feng L, Chignell CF 
In:
Cancer Res (2008) 68(10): 3752-8 
Categories:
Transfection 
Authors:
Belso N, Szell M, Pivarcsi A, Kis K, Kormos B, Kenderessy AS, Dobozy A, Kemeny L, Bata-Csorgo Z 
In:
J Invest Dermatol (2008) 128(3): 634-42 
Categories:
Transfection 
Authors:
He YY, Council SE, Feng L, Bonini MG, Chignell CF 
In:
Photchem Photobiol (2008) 84(1): 69-74 
Categories:
Transfection 
Authors:
Kandert S, Lüke Y, Kleinhenz T, Neumann S, Lu W, Jaeger VM, Munck M, Wehnert M, Müller CR, Zhou Z, Noegel AA, Dabauvalle MC, Karakesisoglou I 
In:
Hum Mol Genet (2007) 16(23): 2944-59 
Categories:
Transfection 
Authors:
Smith JL, Campos SK, Ozbun MA 
In:
J Virol (2007) 81(18): 9922-31 
Categories:
Transfection 
Authors:
Wrighton KH, Willis D, Long J, Liu F, Lin X, Feng XH 
In:
J Biol Chem (2006) 281(50): 38365-75 
Categories:
Transfection 
Authors:
Haugwitz U, Bobkiewicz W, Han SR, Beckmann E, Veerachato G, Shaid S, Biehl S, Dersch K, Bhakdi S, Husmann M 
In:
Cell Microbiol (2006) 8(10): 1591-600 
Categories:
Transfection 
Authors:
Noda D, Itoh S, Watanabe Y, Inamitsu M, Dennler S, Itoh F, Koike S, Danielpour D, Ten Dijke P, Kato M 
In:
Oncogene (2006) 25(41): 5591-600 
Categories:
Transfection 
Authors:
Padmakumar VC, Libotte T, Lu W, Zaim H, Abraham S, Noegel AA, Gotzmann J, Foisner R and Karakesisoglou I 
In:
J Cell Sci (2005) 118(Pt 15): 3419-3430 
Categories:
Transfection 
Authors:
Mirmohammadsadegh A, Tartler U, Michel G, Baer A, Walz M, Wolf R, Ruzicka T and Hengge UR 
In:
J Invest Dermatol (2003) 120: 1045-1051 
Categories:
Transfection 
Authors:
Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E, Brocker EB, Goebeler M, Neumann M and Walczak H. 
In:
Mol Cell Biol (2003) 23(3): 777-790 
+ Show All